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Supplementary Information: Methods Details and Data 
Though next generation sequencing can produce more accurate data with higher sensitivity1, we 
used microarray data because of the availability of a larger number of samples with adequate follow up 
information, which were retrieved from The Cancer Genome Atlas (TCGA) data portal (https://tcga-
data.nci.nih.gov/tcga/) and also availability of an independent dataset, GSE206242, as external test for 
the developed classifier. The Cancer Genome Atlas (TCGA) Research Network has improved our 
understanding in cancer biology through profiling and analyzing large numbers of human tumors. The 
resulting rich data offer a great opportunity to improve a coherent picture of variation across tumors3,4. 
For the purpose of this study, Agilent Microarray (Agilent 244K custom gene expression) data of 1893 
samples from published TCGA (http://tcga-data.nci.nih.gov/tcga/) representing six cancer types 
including breast: breast invasive carcinoma [BRCA, n=531], ovary: ovarian serous 
cystadenocarcinoma [OV, n=578], brain: glioblastoma multiforme [GBM, n=403], kidney: kidney 
renal clear cell carcinoma [KIRC, n=72], colon: colon adenocarcinoma [COAD, n=154] and lung: lung 
squamous cell carcinoma [LUSC, n=155]) were combined, while normal and control samples were 
excluded.  
A list of human glycosyltransferase (GT) genes was retrieved through filtering several publicly 
available databases such as Kyoto Encyclopedia of Genes and Genomes database (KEGG/GENES)  
(http://www.genome.jp/kegg/genes.html), Carbohydrate-Active Enzymes database (CAZy) databases 
(http://www.cazy.org/), and literature search. KEGG/GENES is a pool of manually curated genes 
retrieved mainly from NCBI RefSeq5-7. Furthermore, CAZy provides an online and regularly updated 
access to family classification of CAZymes corresponding to proteins released in the daily releases of 
GenBank (ftp://ftp.ncbi.nih.gov/genbank/daily-nc)8. Supplementary Table 1 contains a list of human 
glycosyltransferase gene symbols with their Entrez numbers.  
The expression dataset of glycosyltransferases was built through combining the TCGA expression 
datasets of six investigated cancer types (i.e. breast, brain, colon, kidney, lung and ovary) and further 
retrieving the expression of 210 glycosyltransferase genes from the combined dataset.  
Batch effects are commonly observed systematic non-biological variation between groups of 
samples due to experimental artifacts, such as processing date, lab, or technician. Combining samples 
from multiple batches can cause the true biological variation in a high-throughput experiment to be 
obscured by variation due to batch9. However, the correlations of batch effects (technical and 
biological artifacts) with the outcome are common and critical to address10, correcting for batch effects 
when there is no significant effects may result in removing biological variation instead of the 
systematic non-biological variation due to batch9. Therefore, a simple test was performed to evaluate 
existing of batch effects in combined dataset with comparing box plots, QQ-plots and applying a t-test 
analysis before and after using an Empirical Bayes batch effect correction method, i.e. ComBat, 
implemented in ‘sva’ package11 in R12. The result of this analysis clearly illustrated that no significant 
batch effects in the dataset (t-test p-value=0.5, Supplementary Figure 1a) and also there is no specific 
color grouping observed based on the batch effects in the principal component loading plot for PC1 to 
PC3 in the combined dataset (Supplementary Figure 1b). However a significant grouping is observed 
while samples are colored based on the cancer type (Fig. 1a) confirming the batch effects do not 
stimulate cancer type grouping. In addition, separate principal component analyses were performed to 
investigate the batch effects in each TCGA cancer type while samples are colored based on the batch 
numbers and they have not shown any grouping based on the batch numbers in each cancer type 
(Supplementary Figure 1c). 
To separate cancer types based on the expression of glycosyltransferase genes, a principal 
component analysis was performed using ‘psych’ package13 in R. Furthermore, a hierarchical average 
linkage clustering performed on GT genes and cancer types across the complete 1893 sample set using 
‘cluster’ package13 in R. The result of this analysis reveals that the expression profile of GT genes not 
only separates six cancer types but also represents a unique molecular entity with similarity to lung 
cancer for basal-like samples (TNBC, n=83, colored in black in the TNBC sidebar in Supplementary 
Figure 2), which is in line with the result of Prat and colleagues (2013) investigating the expression of 
3486 most variable genes across six different cancer types from TCGA data3. 
To better understand how the expression of glycosyltransferase genes contribute to separation of 
cancer types from each other and to investigate dominant glycan-specific changes occur in 
carcinogeneic process of each cancer type, the expression of glycosyltransferase genes was compared 
among the cancer types and the association of glycosyltransferase genes to patient survival was 
studied.  For this purpose, differential expression analyses were carried out using ‘limma’ package14 in 
R. Genes with q-value > 0.005 and 2 fold change were considered as a differentially expressed gene in 
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pairwise comparisons, while a ‘decideTests’ function in ‘limma’ package was used to assigning binary 
values (i.e. 1: up-regulated, -1: down-regulated and 0: not detected) to these genes. Finally, a gene in a 
specific cancer types was considered to be up-regulated if the median of all pairwise comparisons was 
1 and it is down-regulated (-1) in none of the comparisons and wise versa (Supplementary Table 2). 
Correlation between patient survival and glycosyltransferase gene expression was performed using log 
rank test implemented in ‘survival’ package15 in R, while samples in all cancer types were divided into 
two groups for each gene (0: samples that showed gene expression value above median and 1: below 
median), and then compared to each other in terms of overall outcome (Supplementary Table 2). In 
addition, Supplementary Table 3 shows the expression of glycosyltransferase genes between normal 
and malignant in various cancers in several studies. 
Having established that the expression profile of glycosyltransferase genes are able to separate six 
cancers we explore the development of a GT gene classifier using shrunken centroid approach16 in 
‘pamr’ package (http://cran.r-project.org/web/packages/pamr) in R, which is able to identify cancer 
type from a random sample. Furthermore, ‘caret’ package17 in R was used to rank the gene importance 
in a supervised learning model (pam model). 
For the purpose of error estimation of training model (pam classifier) in the assignment of samples 
to the right cancer types, a 10-fold cross validation technique was carried out using ‘pamr’ package in 
R. In addition, internal and independent/external tests were carried out to evaluate the performance of 
the pam classifier using the expression of glycosyltransferase genes. For this purpose, the 
glycosyltranseferases’ expression dataset was randomly split hundred times into training (70%) and test 
(30%) sets. Training sets were used to build a model, which were then applied to the testing sets. 
Finally, the median values were used to assign each sample to a specific cancer type. The result of this 
analysis was used for accuracy measurement calculation summarized in Supplementary Table 4. Given 
a classifier and a sample, there are four possible outcomes: true positive, true negative, false positive 
and false negative. It is true positive if the sample is positive and it is classified as positive and it is 
false negative if it is classified as negative. It is true negative if the sample is negative and it is 
classified as negative and it is a false positive if it is classified as positive. Given a classifier and a set 
of samples (the test set), a two-by-two confusion matrix (also called a contingency table) can be 
constructed representing the dispositions of the set of samples, see Fawcett (2006) for more 
information and equations16. Furthermore, the ROC (Receiver Operating Characteristics) curve has 
been extensively studied and applied in medical diagnosis since the 1970s18,19 and the area under the 
ROC (AUC)20 has become an important performance measure in this regard, since it is invariant to 
operating conditions21. The accuracy measures derived from a confusion matrix, the area under the 
receiver operating characteristic (ROC) curve and its confidence interval (CI) for internal test 
(Supplementary Table 4), clearly shows the potential of gene expression profiling of 
glycosyltransferase in tumor type identification/separation with high accuracy, sensitivity and 
specificity for all investigated cancer types.  
Since training algorithms look for patterns in the training dataset, a classifier that relies on these 
spurious patterns will have higher accuracy on the training examples than it will on the whole 
population. Therefore, it is extremely critical to evaluate the performance of a classifier on an 
independent test set. For this purpose, training sets of previous test (internal test) have been used for an 
external (independent) test that examines 293 breast cancer samples existing in GPL1390 platform of 
GSE206242. GSE20624 (GPL1390) data is not included in TCGA while it uses the same microarray 
platform with TCGA datasets, however, only 177 glycosyltransferase are common between training 
(TCGA based) and this dataset. 
In terms of breast cancer subtyping, to provide a quantitative evidence for the prediction of a 
number of possible clusters within the TCGA breast cancer dataset, consensus clustering plus class 
discovery technique 24 was conducted using ‘ConsensusClusterPlus’ package22 in R. Consensus 
clustering is a clustering framework that has been widely used for cancer subtyping. In this technique, 
the same clustering algorithm is applied multiple times to different subsets of the data and a consensus 
result is collected to better describe the similarities between samples23. The consensus Cumulative 
Distribution Function (CDF) and Delta area plots are the graphical representations to illustrate at what 
number of clusters, the CDF reaches an approximate maximum and at which k (number of groups) 
there is no significant increase in CDF curve, respectively. The result of consensus clustering analysis 
was graphically represented as heatmaps for the consensus matrices of k=2 to k=10. Accordingly, 
microarrays are placed in both rows and columns of the consensus matrices and consensus value ranges 
are colored by white to dark blue, indicating that samples never cluster together and always cluster 
together, respectively (Supplementary Figures 3a and b). Furthermore, to group samples into subtypes 
based on the expression of glycosyltransferase genes, a k-means clustering was performed using 
‘cluster’ package in R. Cluster significance was evaluated using ‘SigClust’ package24 in R, and all class 
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boundaries were statistically significant (Supplementary Figure 3c). To investigate whether the 
identified groups (using k-means clustering), specific to breast cancer may represent clinically distinct 
subgroups of patients, univariate survival analyses (comparing subtypes, k=2 to k=10, with respect to 
the overall survival) was performed (Supplementary Figure 3d) using ‘survival’ package in R, while 
previously identified normal-like25, metastatic samples and the samples with missing survival 






Supplementary Figure 1 | Evaluation of batch effects across combined and separated datasets.  
a, Comparison of sample distribution before and after applying a batch correction method, ComBat11. 
Box plots and QQ-plots illustrate the distribution of samples in dataset before (top) and after (down) 
applying ComBat and a t-test compares these two datasets. b, Visualization of batch effects across 
combined dataset.  Principal component loading plot for PC1-PC3, while samples colored based on the 
batch numbers. c, Evaluation of batch effects within each cancer type. Pairwise principal component 
loading plots for PC1-PC3, while samples are colored based on the batch numbers in each cancer type 
(i.e. breast: breast invasive carcinoma [BRCA, n=531], ovary: ovarian serous cystadenocarcinoma 
[OV, n=578], brain: glioblastoma multiforme [GBM, n=403], kidney: kidney renal clear cell carcinoma 
[KIRC, n=72], colon: colon adenocarcinoma [COAD, n=154] and lung: lung squamous cell carcinoma 


















































































































































































































































































































































Supplementary Figure 3 | Identification of breast cancer subtypes using 
glycosyltransferase expression profile.  
a, Consensus clustering matrix of 467 breast cancer TCGA samples for k=3 to k=6. b, 
Consensus CDF for k=2 to k=10. c, SigClust p-values for all pairwise comparisons of five 
clusters/groups. d, Log rank test p-values investigating the relation of number of subtypes 







Supplementary Table 1 | List of 210 glycosyltransferase genes presented in TCGA 
Agilent microarray expression datasets. 
Gene symbol Entrez ID. Gene symbol Entrez ID. Gene symbol Entrez ID. 
A3GALT2 127550 FUT11 170384 MGAT3 4248 
A4GALT 53947 FUT2 2524 MGAT4A 11320 
A4GNT 51146 FUT3 2525 MGAT4B 11282 
ABO 28 FUT4 2526 MGAT5 4249 
ALG10 84920 FUT5 2527 MGAT5B 146664 
ALG11 440138 FUT6 2528 NAGA 4668 
ALG12 79087 FUT7 2529 NEU1 4758 
ALG13 55849 FUT8 2530 NEU2 4759 
ALG14 199857 FUT9 10690 NEU3 10825 
ALG2 85365 GAL 51083 NEU4 129807 
ALG3 10195 GALC 2581 OGT 8473 
ALG5 29880 GALNT10 55568 PIGA 5277 
ALG6 29929 GALNT11 63917 PIGB 9488 
ALG8 79053 GALNT12 79695 PIGC 5279 
ALG9 79796 GALNT13 114805 PIGH 5283 
B3GALNT1 8706 GALNT14 79623 PIGM 93183 
B3GALNT2 148789 GALNT2 2590 PIGP 51227 
B3GALT1 8708 GALNT3 2591 PIGQ 9091 
B3GALT2 8707 GALNT4 8693 PIGV 55650 
B3GALT4 8705 GALNT5 11227 PIGX 54965 
B3GALT5 10317 GALNT6 11226 PIGY 84992 
B3GALT6 126792 GALNT7 51809 PIGZ 80235 
B3GALTL 145173 GALNT8 26290 PLOD3 8985 
B3GAT1 27087 GALNT9 50614 POFUT1 23509 
B3GAT3 26229 GALNTL1 57452 POFUT2 23275 
B3GNT1 11041 GALNTL2 117248 POMGNT1 55624 
B3GNT2 10678 GALNTL4 374378 POMT1 10585 
B3GNT3 10331 GALNTL5 168391 POMT2 29954 
B3GNT4 79369 GALT 2592 PYGM 5837 
B3GNT5 84002 GBGT1 26301 RFNG 5986 
B3GNT6 192134 GCNT1 2650 RPN1 6184 
B3GNT7 93010 GCNT2 2651 RPN2 6185 
B3GNT8 374907 GCNT3 9245 ST3GAL1 6482 
B3GNTL1 146712 GCNT4 51301 ST3GAL2 6483 
B4GALNT1 2583 GGTA1 2681 ST3GAL3 6487 
B4GALNT2 124872 GLA 2717 ST3GAL4 6484 
B4GALNT3 283358 GLB1 2720 ST3GAL5 8869 
B4GALNT4 338707 GLT1D1 144423 ST3GAL6 10402 
B4GALT2 8704 GLT25D1 79709 ST6GAL1 6480 
B4GALT3 8703 GLT25D2 23127 ST6GAL2 84620 
B4GALT4 8702 GLT6D1 360203 ST6GALNAC1 55808 
B4GALT5 9334 GLT8D1 55830 ST6GALNAC2 10610 
B4GALT6 9331 GLT8D2 83468 ST6GALNAC3 256435 
B4GALT7 11285 GLT8D3 283464 ST6GALNAC4 27090 
C1GALT1 56913 GLT8D4/GXYLT2 727936 ST6GALNAC5 81849 
C1GALT1C1 29071 GTDC1 79712 ST6GALNAC6 30815 
CEECAM1 51148 GYG1 2992 ST8SIA1 6489 
CHGN/GALNA
CT1 55790 GYG2 8908 ST8SIA2 8128 
CHPF 79586 GYLTL1B 120071 ST8SIA3 51046 
CHSY.2 337876 GYS1 2997 ST8SIA4 7903 
CHSY1 22856 GYS2 2998 ST8SIA5 29906 
CSGLCA.T 54480 HAS1 3036 STT3A 3703 
DAD1 1603 HAS2 3037 STT3B 201595 
DDOST 1650 HAS3 3038 UGCG 7357 
DPAGT1 1798 KDELC1 79070 UGT1A6 54578 
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DPM1 8813 KDELC2 143888 UGT1A8 54576 
DPM2 8818 KTELC1 56983 UGT2A1 10941 
DPM3 54344 LARGE 9215 UGT2B10 7365 
EIF2B3 8891 LFNG 3955 UGT2B11 10720 
EIF2B5 8893 LOC152586 152586 UGT2B15 7366 
EXT1 2131 MAN1A1 4121 UGT2B17 7367 
EXT2 2132 MAN1A2 10905 UGT2B28 54490 
EXTL1 2134 MAN1B1 11253 UGT2B4 7363 
EXTL2 2135 MAN1C1 57134 UGT2B7 7364 
EXTL3 2137 MAN2A1 4124 UGT3A1 133688 
FLJ21865 64772 MAN2A2 4122 UGT3A2 167127 
FUCA1 2517 MANBA 4126 UGT8 7368 
FUCA2 2519 MFNG 4242 WBSCR17 64409 
FUT1 2523 MGAT1 4245 XYLT1 64131 
FUT10 84750 MGAT2 4247 XYLT2 64132   
 
 
Supplementary Table 2 | List of differentially expressed glycosyltransferase genes in 
six cancer types compare to each other along with log rank test p-value of each gene 
in survival analysis. BRCA: breast cancer; COAD: colon cancer; GBM: brain; KIRC: 
kidney; LUSC: lung; OV: ovarian; ↑: up-regulated; ↓: down-regulated; ☐: not detected. 
Glycan structure 
abberation Gene symbol 
Cancer type Log rank 
test  
p-value BRCA COAD GBM KIRC LUSC OV 
N-glycans                 
Precursor synthesis                 
  ALG10 ☐	 ↑	 ↓	 ☐	 ↑	 ↑	 5.11E-15 
  ALG11 ☐	 ↑	 ↓	 ☐	 ↑	 ↓	 0.00E+00 
  ALG12 ↑	 ☐	 ↓	 ☐	 ☐	 ↓	 0.00E+00 
  ALG3 ☐	 ↑	 ↓	 ↓	 ↑	 ↑	 1.22E-06 
  ALG5 ↓	 ↑	 ☐	 ☐	 ☐	 ↓	 8.01E-01 
Branching   		 		 		 		 		 		   
  MGAT4B ↓	 ↑	 ↓	 ☐	 ↓	 ☐	 5.28E-08 
  MGAT5B ↓	 ↓	 ↑	 ↓	 ↓	 ↓	 0.00E+00 
Biosecting   		 		 		 		 		 		   
  MGAT3 ↓	 ↓	 ↑	 ☐	 ↓	 ↑	 0.00E+00 
Core fucosylation   		 		 		 		 		 		   
  FUT8 ↑	 ☐	 ☐	 ↓	 ↑	 ↑	 7.27E-06 
Increased α2,6-
sialylation ST6GAL1 ↓	 ↑	 ↓	 ☐	 ↓	 ☐	 2.77E-01 
O-glycans   		 		 		 		 		 		   
Tn   		 		 		 		 		 		   
  GALNT10 ☐	 ☐	 ☐	 ☐	 ☐	 ↓	 7.65E-01 
  GALNT12 ↓	 ↑	 ↓	 ☐	 ☐	 ☐	 7.96E-02 
  GALNT13 ↓	 ↓	 ↑	 ↓	 ☐	 ☐	 0.00E+00 
  GALNT14 ☐	 ↓	 ☐	 ↓	 ☐	 ☐	 2.26E-05 
  GALNT3 ☐	 ↑	 ↓	 ↓	 ↑	 ↑	 6.66E-15 
  GALNT4 ↓	 ↑	 ↓	 ↓	 ↓	 ☐	 8.29E-13 
  GALNT5 ☐	 ↑	 ☐	 ↓	 ☐	 ↓	 7.82E-01 
  GALNT6 ↑	 ↑	 ↓	 ↓	 ☐	 ↑	 0.00E+00 
  GALNT7 ↑	 ↑	 ↓	 ↓	 ☐	 ↓	 0.00E+00 
  GALNT8 ↓	 ↑	 ↓	 ↓	 ↓	 ↓	 0.00E+00 
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  GALNT9 ↓	 ↓	 ☐	 ↑	 ↓	 ↓	 0.00E+00 
  GALNTL1 ↑	 ↓	 ↑	 ☐	 ↓	 ☐	 1.55E-03 
  GALNTL2 ↓	 ↓	 ↑	 ☐	 ↓	 ↓	 5.27E-13 
  GALNTL4 ↓	 ↓	 ☐	 ↑	 ↑	 ↓	 7.18E-01 
  GALNTL5 ↓	 ↓	 ↑	 ↓	 ↓	 ↓	 0.00E+00 
SialylTn (sTn)   		 		 		 		 		 		   
  ST6GALNAC1 ↓	 ↑	 ☐	 ↓	 ☐	 ☐	 7.93E-01 
  ST6GALNAC2 ↑	 ↓	 ↓	 ↓	 ↑	 ↑	 0.00E+00 
  ST6GALNAC3 ↓	 ↓	 ↑	 ↑	 ↓	 ↓	 0.00E+00 
  ST6GALNAC5 ↑	 ☐	 ☐	 ↓	 ↑	 ↑	 6.08E-02 
  ST6GALNAC6 ☐	 ↓	 ↑	 ☐	 ☐	 ☐	 2.94E-13 
SialylT (sT)   		 		 		 		 		 		   
  ST3GAL1 ↑	 ↓	 ↓	 ↑	 ↑	 ↑	 0.00E+00 
Lewis antigens   		 		 		 		 		 		   
Sialyl Le(a)   		 		 		 		 		 		   
  ST3GAL3 ↓	 ↓	 ↑	 ↑	 ↑	 ☐	 0.00E+00 
  B3GALT1 ↓	 ☐	 ↑	 ↓	 ↓	 ☐	 0.00E+00 
  B3GALT2 ↓	 ↓	 ↑	 ↓	 ↓	 ↓	 0.00E+00 
  B3GALT5 ☐	 ↑	 ↓	 ☐	 ↓	 ↓	 5.02E-07 
  B3GALTL ↓	 ☐	 ↑	 ☐	 ☐	 ↓	 1.15E-10 
  FUT3 ☐	 ↑	 ↓	 ☐	 ☐	 ☐	 0.00E+00 
Sialyl Le(x)   		 		 		 		 		 		   
  ST3GAL3 ↓	 ↓	 ↑	 ↑	 ↑	 ☐	 0.00E+00 
  ST3GAL6 ↓	 ↓	 ↑	 ↑	 ☐	 ↑	 0.00E+00 
  B4GALT4 ↓	 ☐	 ↓	 ↓	 ↑	 ☐	 8.51E-01 
  B4GALT6 ↓	 ↑	 ☐	 ☐	 ☐	 ☐	 1.47E-07 
  FUT3 ☐	 ↑	 ↓	 ☐	 ☐	 ☐	 0.00E+00 
  FUT4 ↓	 ↑	 ↓	 ↓	 ↓	 ↓	 1.91E-07 
  FUT5 ↓	 ↑	 ↓	 ☐	 ☐	 ↓	 3.37E-05 
  FUT6 ↓	 ↑	 ☐	 ↑	 ↓	 ↓	 7.62E-07 
Glycosphingolipids   		 		 		 		 		 		   
Polysialic acid 
(PSA) linked to 
NCAM/SSEA-4 
  		 		 		 		 		 		   
  ST8SIA1 ☐	 ↓	 ↑	 ↓	 ☐	 ↓	 0.00E+00 
  ST8SIA3 ↓	 ↓	 ↑	 ↓	 ↓	 ↓	 0.00E+00 
  ST8SIA4 ☐ ↓ ☐ ↑ ☐ ☐ 3.52E-06 
  ST8SIA5 ↓ ↓ ↑ ↓ ↓ ☐ 0.00E+00 
  A4GALT ☐ ↓ ↓ ↑ ↑ ↓ 0.00E+00 
Gb3                 
  ST3GAL5 ☐ ↓ ↑ ☐ ☐ ↓ 0.00E+00 
  B4GALNT1 ↓ ↓ ↑ ↓ ↑ ↓ 0.00E+00 
  FUT1 ↑ ↑ ↓ ☐ ↑ ↑ 0.00E+00 






Supplementary Table 3 | Cell surface glycan changes and glycosyltransferase regulation 
between normal and malignant in various cancers. ↑: up-regulated; ↓: down-regulated. 
Glycan structure 




Precursor synthesis  
 
  
  ALG10 breast↑ 26 








  MGAT3 breast↓,colon↑,lung↑,kidney↑,ovarian↑ 26-32 
Core fucosylation  
 
  
  FUT8 breast↑, colon↑,ovarian↑ 26,31-33  
Increased α2,6-







  GALNT10 breast↑ 26,39 
  GALNT12 breast↓ 26 
  GALNT14 lung↑ 40 
  GALNT3 breast↑,colon↑ 26,39,41 
  GALNT4 breast↑,kidney↑ 26,42 
  GALNT5 breast↑ 26,39  
  GALNT6 breast↑,ovarian↑ 26,39,43 
  GALNT7 breast↑ 26,39  
SialylTn (sTn)  
 
  
  ST6GALNAC2 breast↑ 39 
  ST6GALNAC3 breast↓ 26 
  ST6GALNAC5 brain↓ 36 
  ST6GALNAC6 breast↓,brain↓ 26,36 
SialylT (sT)  
 
  
  ST3GAL1 breast↑,colon↑,ovarian↑ 26,38,44-48 
Lewis antigens  
 
  
Sialyl Le(a)  
 
  
  ST3GAL3 breast↓,ovarian↓,colon↑ 26,38,39,49  
  B3GALT2 lung↓ 50 
  FUT3 breast↑,colon↓↑,brain↑,lung↑,ovarian↑ 29,36,39,51-57 
Sialyl Le(x)  
 
  
  ST3GAL3 breast↓,ovarian↓,colon↑ 26,38,39,49 
  ST3GAL6 breast↓↑,brain↓,ovarian↓ 26,29,38,44,55,58 
  FUT3 breast↑,colon↓↑,brain↑,lung↑,ovarian↑ 36,39,51-57 
  FUT4 breast↓↑,colon↑,lung↑,ovarian↑ 26,29,39,47,52,55,56,59,60 
  FUT5 breast↑, ovarian↑ 39,55,56 



















  ST3GAL5 ovarian↓↑ 38,66 
  B4GALNT1 brain↑ 67 
  FUT1 breast↑,colon↑,ovarian↑ 47,52,60,68-70  





Supplementary Table 4 | Accuracy measurements for the classifier using 
result of internal test. Accuracy measures derived from a confusion matrix, 
the area under the receiver operating characteristic (ROC) curve and its 
confidence interval (CI). 
Measurement 
Cancer type 
BRCA COAD GBM KIRC LUSC OV 
Overall diagnostic 
power 0.71  0.91 0.78 0.96 0.91 0.69 
Correct 
classification rate 0.98 0.99 0.99 0.99 0.99 0.99 
Sensitivity 0.95 0.98 0.99 0.94 0.93 0.98 
Specificity 0.99 0.98 0.99 0.99 0.99 0.99 
False positive rate 1.5e-3 6.0e-4 1.3e-3 5.0e-4 2.3e-3 5.3e-3 
False negative rate 4.7e-2 1.3e-2 7.4e-3 5.5e-2 6.4e-2 1.3e-2 
Positive predictive 
power 0.99 0.99 0.99 0.98 0.97 0.98 
Negative predictive 
power 0.98 0.99 0.99 0.99 0.99 0.99 
Misclassification 
rate 1.4e-2 1.6e-3 2.6e-3 2.6e-3 7.4e-3 7.9e-3 
Kappa 0.96 0.98 0.99 0.96 0.94 0.98 
NMI n(s) 0.87 0.95 0.96 0.88 0.85 0.92 
Area under the 
curve (%) 99.99 99.87 99.97 100 99.88 99.94 












*Diagnostic Power (DP) is determined by both its sensitivity and its specificity and it is the 
proportion correctly classified74. 
BRCA: breast invasive carcinoma (n=531), COAD: colon adenocarcinoma (n=154), GBM: 
glioblastoma multiforme (n=403), KIRC: kidney renal clear cell carcinoma (n=72), LUSC: lung 
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